55
Participants
Start Date
March 15, 2021
Primary Completion Date
December 1, 2024
Study Completion Date
July 1, 2027
Atezolizumab + Trastuzumab + Vinorelbine
"* Atezolizumab IV 1200 mg in combination with~* Trastuzumab sc 600mg or IV 6mg/kg every 3 weeks and~* Vinorelbine 25 mg/m² IV or 60 mg/m2 PO on days 1 and 8, every 3 weeks during the first cycle and if there are no toxicity signs dose will be increased to 80 mg/m2 PO o 30 mg/m2 IV."
Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña
Hospital de León, León
Hospital Universitario de Canarias, Santa Cruz de Tenerife
Hospital Universitari Sant Joan de Reus, Reus
H. Clínico San Cecilio de Granada, Granada
Institut Català d'Oncologia Hospitalet, L'Hospitalet de Llobregat
Hospital General Universitario de Alicante, Alicante
Hospital Clinic de Barcelona, Barcelona
Hospital Universitari Vall d' Hebron, Barcelona
Hospital San Pedro de Alcántara, Cáceres
Hospital Universitario 12 de octubre, Madrid
Hospital Son Espases, Palma de Mallorca
Hospital Universitario Virgen del Rocio, Seville
Hospital Clinico Universitario de Valencia, Valencia
Hospital del Mar, Barcelona
Roche Pharma AG
INDUSTRY
SOLTI Breast Cancer Research Group
OTHER